Bruno Sangro, MD, PhD

Transarterial Chemoembolization with Durvalumab or Durvalumab + Bevacizumab in Patients with Locoregional Hepatocellular Carcinoma: EMERALD-1

Purpose: Because curative therapy is not always feasible and there is no standard systemic therapy, patients with intermediate-stage hepatocellular carcinoma (HCC) are treated with locore...

Shukui Qin , MD, PhD;

Zhenggang Ren ;

Joseph Erinjeri ;

Shethah Morgan ;

Gordon Cohen ;

Yasuaki Arai , MD;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Stephen Lam Chan , MD;

Masatoshi Kudo , MD, PhD;

10/21/2019

CIO 2020-4 Transarterial Chemoembolization Combined With Durvalumab±Bevacizumab in Patients With Locoregional HCC (EMERALD-1)

Yasuaki Arai , MD;

Zhenggang Ren ;

Joseph Erinjeri ;

Philip He ;

Shethah Morgan ;

Gordon Cohen ;

Riccardo Lencioni , MD;

Bruno Sangro , MD, PhD;

Masatoshi Kudo , MD, PhD;

Stephen Lam Chan , MD;

Shukui Qin , MD, PhD;

07/23/2021

CIO 2022-3 Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma

Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...

Siddharth A. Padia , MD;

S. Cheenu Kappadath , PhD;

Riad Salem , MD, MBA;

Bruno Sangro , MD, PhD;

Edward Kim , MD;

Daniel Sze , MD, PhD;

Marnix Lam ;

Carlo Chiesa ;

Paul Haste ;

Beau Toskich ;

Kirk Fowers ;

Joseph M. Herman ;

Thomas Leung ;

Etienne Garin ;

10/18/2022

CIO 2023-1 Four-year Overall Survival from the HIMALAYA Study of Tremelimumab + Durvalumab in Unresectable Hepatocellular Carcinoma

Purpose: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Re...

Yoon-Koo Kang , MD, PhD;

Charu Gupta , MSc;

Maria Reig , MD, PhD;

Peter R. Galle , MD, PhD;

Alejandra Negro , PhD;

Masatoshi Kudo , MD, PhD;

Bruno Sangro , MD, PhD;

George Tat-Ming Lau , MBBS, FRACP, MD, PhD;

Valeriy Vladimirovich Breder , MD, PhD;

Stephen Lam Chan , MD;

Robin Kate Kelley , MD;

Wattana Sukeepaisarnjaroen , MD;

Enrico De Toni , MD, PhD;

Junji Furuse , MD, PhD;

Lorenza Rimassa , MD;

Alexandra Heurgué , MD;

Vincent Tam , MD;

Tu Van Dao , MD, PhD;

Satheesh Chiradoni Thungappa , MD;

Yuriy Ostapenko , MD;

Mallory Makowsky , PharmD;

11/01/2023

Bruno Sangro, MD, PhD, Clínica Universidad de Navarra

Videos

Long-Term OS Benefit of STRIDE Regimen Among Patients With Unresectable Hepatocellular Carcinoma

08/21/2023

Bruno Sangro , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Bruno Sangro, MD, PhD, discusses 4-year overall survival results from the phase 3 HIMALYA study.

At the 2023 World Congress on...

08/21/2023

Oncology